Comments
Dr Reddy’s Laboratories Ltd has announced the closure of transactions with Upsher-Smith Laboratories, LLC (Upsher-Smith). This follows the satisfactory completion of all customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Under the agreement Dr Reddy’s sold its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, which were commercialised through its wholly-owned subsidiary, Promius Pharma, LLC.
Upsher-Smith Laboratories is a US pharmaceutical company that has brought generics and brands to a wide array of customers, backed by service and industry relationships.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.